Is Shopify Stock a Good Buy Now?
eCommerce technology platform Shopify (NASDAQ:SHOP) delivered impressive returns in 2025…
Sell
43
IBRX Quote, Financials, Valuation and Earnings
Last price:
$2.34
Seasonality move
:
74.15%
Day range:
$2.26 - $2.43
52-week range:
$1.83 - $4.27
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
24.15x
P/B ratio:
--
Volume:
12.5M
Avg. volume:
13.2M
1-year change:
-8.98%
Market cap:
$2.3B
Revenue:
$14.7M
EPS (TTM):
-$0.42
Price Performance History
Performance vs. Valuation Benchmarks
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Competitors
| Company | Revenue Forecast | Earnings Forecast | Revenue Growth Forecast | Earnings Growth Forecast | Analyst Price Target Median |
|---|---|---|---|---|---|
|
IBRX
ImmunityBio, Inc.
|
$39.3M | -$0.07 | 376.51% | -3.61% | $10.40 |
|
ALT
Altimmune, Inc.
|
$710 | -$0.26 | -85.8% | -1.45% | $17.75 |
|
CORT
Corcept Therapeutics, Inc.
|
$200.8M | $0.05 | 27.74% | -71.78% | $91.00 |
|
CYTK
Cytokinetics, Inc.
|
$15.1M | -$1.55 | 857.99% | -14.11% | $88.22 |
|
MCRB
Seres Therapeutics, Inc.
|
-- | -$1.60 | -100% | -11.49% | $21.00 |
|
RLAY
Relay Therapeutics, Inc.
|
$16.7K | -$0.43 | -99.89% | -12.85% | $14.60 |
| Company | Price | Analyst Target | Market Cap | P/E Ratio | Dividend per Share | Dividend Yield | Price / LTM Sales |
|---|---|---|---|---|---|---|---|
|
IBRX
ImmunityBio, Inc.
|
$2.33 | $10.40 | $2.3B | -- | $0.00 | 0% | 24.15x |
|
ALT
Altimmune, Inc.
|
$4.02 | $17.75 | $419.5M | -- | $0.00 | 0% | 15,964.63x |
|
CORT
Corcept Therapeutics, Inc.
|
$37.50 | $91.00 | $3.9B | 42.85x | $0.00 | 0% | 6.05x |
|
CYTK
Cytokinetics, Inc.
|
$62.51 | $88.22 | $7.6B | -- | $0.00 | 0% | 85.30x |
|
MCRB
Seres Therapeutics, Inc.
|
$15.65 | $21.00 | $137M | 25.78x | $0.00 | 0% | 388.80x |
|
RLAY
Relay Therapeutics, Inc.
|
$7.99 | $14.60 | $1.4B | -- | $0.00 | 0% | 162.61x |
| Company | Total Debt / Total Capital | Beta | Debt to Equity | Quick Ratio |
|---|---|---|---|---|
|
IBRX
ImmunityBio, Inc.
|
255.62% | 1.859 | 35.53% | 5.07x |
|
ALT
Altimmune, Inc.
|
7.89% | 0.672 | 4.41% | 16.79x |
|
CORT
Corcept Therapeutics, Inc.
|
1% | -3.281 | 0.07% | 2.85x |
|
CYTK
Cytokinetics, Inc.
|
177.12% | 1.240 | 17.83% | 6.81x |
|
MCRB
Seres Therapeutics, Inc.
|
66.11% | 2.425 | 50.61% | 2.16x |
|
RLAY
Relay Therapeutics, Inc.
|
5.2% | 2.761 | 3.7% | 18.29x |
| Company | Gross Profit | Operating Income | Return on Invested Capital | Return on Common Equity | EBIT Margin | Free Cash Flow |
|---|---|---|---|---|---|---|
|
IBRX
ImmunityBio, Inc.
|
$27.9M | -$55.6M | -122.87% | -- | -173.51% | -$69.7M |
|
ALT
Altimmune, Inc.
|
-$22K | -$20.9M | -53.6% | -56.24% | -417180% | -$11.9M |
|
CORT
Corcept Therapeutics, Inc.
|
$203M | $10.2M | 15.84% | 16% | 4.92% | $54.5M |
|
CYTK
Cytokinetics, Inc.
|
-$743K | -$166.8M | -120.55% | -- | -8613.38% | -$116.9M |
|
MCRB
Seres Therapeutics, Inc.
|
-$693K | -$22.5M | 4.41% | 16.36% | -6403.7% | $2.2M |
|
RLAY
Relay Therapeutics, Inc.
|
-$748K | -$80.4M | -38.91% | -41.21% | -11351.11% | -$62.1M |
ImmunityBio, Inc. vs. Competitors
-
Which has Higher Returns IBRX or ALT?
Altimmune, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -380280%. ImmunityBio, Inc.'s return on equity of -- beat Altimmune, Inc.'s return on equity of -56.24%.
Company Gross Margin Earnings Per Share Invested Capital IBRXImmunityBio, Inc.87.13% -$0.07 $337.8M ALTAltimmune, Inc.-440% -$0.21 $201.5M -
What do Analysts Say About IBRX or ALT?
ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 346.35%. On the other hand Altimmune, Inc. has an analysts' consensus of $17.75 which suggests that it could grow by 341.54%. Given that ImmunityBio, Inc. has higher upside potential than Altimmune, Inc., analysts believe ImmunityBio, Inc. is more attractive than Altimmune, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IBRXImmunityBio, Inc.4 0 0 ALTAltimmune, Inc.5 1 1 -
Is IBRX or ALT More Risky?
ImmunityBio, Inc. has a beta of -0.100, which suggesting that the stock is 110.024% less volatile than S&P 500. In comparison Altimmune, Inc. has a beta of 0.037, suggesting its less volatile than the S&P 500 by 96.298%.
-
Which is a Better Dividend Stock IBRX or ALT?
ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Altimmune, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Altimmune, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IBRX or ALT?
ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Altimmune, Inc. quarterly revenues of $5K. ImmunityBio, Inc.'s net income of -$67.3M is lower than Altimmune, Inc.'s net income of -$19M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Altimmune, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 24.15x versus 15,964.63x for Altimmune, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IBRXImmunityBio, Inc.24.15x -- $32.1M -$67.3M ALTAltimmune, Inc.15,964.63x -- $5K -$19M
-
Which has Higher Returns IBRX or CORT?
Corcept Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of 9.32%. ImmunityBio, Inc.'s return on equity of -- beat Corcept Therapeutics, Inc.'s return on equity of 16%.
Company Gross Margin Earnings Per Share Invested Capital IBRXImmunityBio, Inc.87.13% -$0.07 $337.8M CORTCorcept Therapeutics, Inc.97.79% $0.16 $638.3M -
What do Analysts Say About IBRX or CORT?
ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 346.35%. On the other hand Corcept Therapeutics, Inc. has an analysts' consensus of $91.00 which suggests that it could grow by 142.67%. Given that ImmunityBio, Inc. has higher upside potential than Corcept Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Corcept Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IBRXImmunityBio, Inc.4 0 0 CORTCorcept Therapeutics, Inc.3 1 1 -
Is IBRX or CORT More Risky?
ImmunityBio, Inc. has a beta of -0.100, which suggesting that the stock is 110.024% less volatile than S&P 500. In comparison Corcept Therapeutics, Inc. has a beta of 0.232, suggesting its less volatile than the S&P 500 by 76.804%.
-
Which is a Better Dividend Stock IBRX or CORT?
ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Corcept Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Corcept Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IBRX or CORT?
ImmunityBio, Inc. quarterly revenues are $32.1M, which are smaller than Corcept Therapeutics, Inc. quarterly revenues of $207.6M. ImmunityBio, Inc.'s net income of -$67.3M is lower than Corcept Therapeutics, Inc.'s net income of $19.4M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Corcept Therapeutics, Inc.'s PE ratio is 42.85x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 24.15x versus 6.05x for Corcept Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IBRXImmunityBio, Inc.24.15x -- $32.1M -$67.3M CORTCorcept Therapeutics, Inc.6.05x 42.85x $207.6M $19.4M
-
Which has Higher Returns IBRX or CYTK?
Cytokinetics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -15814.98%. ImmunityBio, Inc.'s return on equity of -- beat Cytokinetics, Inc.'s return on equity of --.
Company Gross Margin Earnings Per Share Invested Capital IBRXImmunityBio, Inc.87.13% -$0.07 $337.8M CYTKCytokinetics, Inc.-38.38% -$2.55 $675.7M -
What do Analysts Say About IBRX or CYTK?
ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 346.35%. On the other hand Cytokinetics, Inc. has an analysts' consensus of $88.22 which suggests that it could grow by 41.13%. Given that ImmunityBio, Inc. has higher upside potential than Cytokinetics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Cytokinetics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IBRXImmunityBio, Inc.4 0 0 CYTKCytokinetics, Inc.10 3 0 -
Is IBRX or CYTK More Risky?
ImmunityBio, Inc. has a beta of -0.100, which suggesting that the stock is 110.024% less volatile than S&P 500. In comparison Cytokinetics, Inc. has a beta of 0.553, suggesting its less volatile than the S&P 500 by 44.718%.
-
Which is a Better Dividend Stock IBRX or CYTK?
ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Cytokinetics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Cytokinetics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IBRX or CYTK?
ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Cytokinetics, Inc. quarterly revenues of $1.9M. ImmunityBio, Inc.'s net income of -$67.3M is higher than Cytokinetics, Inc.'s net income of -$306.2M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Cytokinetics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 24.15x versus 85.30x for Cytokinetics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IBRXImmunityBio, Inc.24.15x -- $32.1M -$67.3M CYTKCytokinetics, Inc.85.30x -- $1.9M -$306.2M
-
Which has Higher Returns IBRX or MCRB?
Seres Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of --. ImmunityBio, Inc.'s return on equity of -- beat Seres Therapeutics, Inc.'s return on equity of 16.36%.
Company Gross Margin Earnings Per Share Invested Capital IBRXImmunityBio, Inc.87.13% -$0.07 $337.8M MCRBSeres Therapeutics, Inc.-197.44% $0.94 $129M -
What do Analysts Say About IBRX or MCRB?
ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 346.35%. On the other hand Seres Therapeutics, Inc. has an analysts' consensus of $21.00 which suggests that it could grow by 34.19%. Given that ImmunityBio, Inc. has higher upside potential than Seres Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Seres Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IBRXImmunityBio, Inc.4 0 0 MCRBSeres Therapeutics, Inc.1 2 0 -
Is IBRX or MCRB More Risky?
ImmunityBio, Inc. has a beta of -0.100, which suggesting that the stock is 110.024% less volatile than S&P 500. In comparison Seres Therapeutics, Inc. has a beta of 0.221, suggesting its less volatile than the S&P 500 by 77.911%.
-
Which is a Better Dividend Stock IBRX or MCRB?
ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Seres Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Seres Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IBRX or MCRB?
ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Seres Therapeutics, Inc. quarterly revenues of $351K. ImmunityBio, Inc.'s net income of -$67.3M is lower than Seres Therapeutics, Inc.'s net income of $8.2M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Seres Therapeutics, Inc.'s PE ratio is 25.78x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 24.15x versus 388.80x for Seres Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IBRXImmunityBio, Inc.24.15x -- $32.1M -$67.3M MCRBSeres Therapeutics, Inc.388.80x 25.78x $351K $8.2M
-
Which has Higher Returns IBRX or RLAY?
Relay Therapeutics, Inc. has a net margin of -209.83% compared to ImmunityBio, Inc.'s net margin of -10395.13%. ImmunityBio, Inc.'s return on equity of -- beat Relay Therapeutics, Inc.'s return on equity of -41.21%.
Company Gross Margin Earnings Per Share Invested Capital IBRXImmunityBio, Inc.87.13% -$0.07 $337.8M RLAYRelay Therapeutics, Inc.-48.01% -$0.43 $641M -
What do Analysts Say About IBRX or RLAY?
ImmunityBio, Inc. has a consensus price target of $10.40, signalling upside risk potential of 346.35%. On the other hand Relay Therapeutics, Inc. has an analysts' consensus of $14.60 which suggests that it could grow by 82.73%. Given that ImmunityBio, Inc. has higher upside potential than Relay Therapeutics, Inc., analysts believe ImmunityBio, Inc. is more attractive than Relay Therapeutics, Inc..
Company Buy Ratings Hold Ratings Sell Ratings IBRXImmunityBio, Inc.4 0 0 RLAYRelay Therapeutics, Inc.9 1 0 -
Is IBRX or RLAY More Risky?
ImmunityBio, Inc. has a beta of -0.100, which suggesting that the stock is 110.024% less volatile than S&P 500. In comparison Relay Therapeutics, Inc. has a beta of 1.548, suggesting its more volatile than the S&P 500 by 54.758%.
-
Which is a Better Dividend Stock IBRX or RLAY?
ImmunityBio, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Relay Therapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. ImmunityBio, Inc. pays -- of its earnings as a dividend. Relay Therapeutics, Inc. pays out -- of its earnings as a dividend.
-
Which has Better Financial Ratios IBRX or RLAY?
ImmunityBio, Inc. quarterly revenues are $32.1M, which are larger than Relay Therapeutics, Inc. quarterly revenues of --. ImmunityBio, Inc.'s net income of -$67.3M is higher than Relay Therapeutics, Inc.'s net income of -$74.1M. Notably, ImmunityBio, Inc.'s price-to-earnings ratio is -- while Relay Therapeutics, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for ImmunityBio, Inc. is 24.15x versus 162.61x for Relay Therapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.
Company Price/Sales Ratio Price/Earnings Ratio Quarterly Revenue Quarterly Net Income IBRXImmunityBio, Inc.24.15x -- $32.1M -$67.3M RLAYRelay Therapeutics, Inc.162.61x -- -- -$74.1M
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will The Magnificent 7 Stocks Go Up This Year?
2025 was another banner year for the Magnificent Seven stocks,…
Why Did Planet Labs Stock Rally So Much?
Satellite imaging startup Planet Labs (NYSE:PL), after years of disappointing…
Stock Ideas
Buy
52
Is NVDA Stock a Buy?
Market Cap: $4.5T
P/E Ratio: 63x
Buy
65
Is GOOG Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Buy
51
Is GOOGL Stock a Buy?
Market Cap: $4T
P/E Ratio: 41x
Alerts
Buy
100
ATGL alert for Jan 10
Alpha Technology Group Ltd. [ATGL] is up 47.05% over the past day.
Buy
71
NAIL alert for Jan 10
Direxion Daily Homebuilders & Supplies Bull 3X Shs [NAIL] is up 18.52% over the past day.
Buy
54
LGIH alert for Jan 10
LGI Homes, Inc. [LGIH] is up 13.81% over the past day.
